Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | September 29, 2022

New biopharmaceutical drug products that alter and even save lives can be very profitable for their developers.

whitePaper | February 16, 2023

Monoclonal antibody drugs (mAbs) make up more than 50 percent of the biologics on the market today, as well as a significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

whitePaper | November 25, 2022

Satyendra Sinha is a Functional Consultant with the TCS Life Sciences unit, and focuses on order management, distribution.

whitePaper | March 6, 2022

Pharmaceutical companies with a medical mindset and an empowered Medical Afairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates.

whitePaper | January 21, 2023

Emerging Diseases Require New Tools Medicines to treat and prevent infectious diseases cover a broad range of modalities from dosed therapeutics to vaccines. Biotherapeutics require a detailed knowledge of binding sites, or epitopes, on their respective antigens.

whitePaper | December 28, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical.